+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Prognostic significance of histology after resection of brain metastases and whole brain radiotherapy in non-small cell lung cancer (NSCLC)



Prognostic significance of histology after resection of brain metastases and whole brain radiotherapy in non-small cell lung cancer (NSCLC)



Clinical and Experimental Metastasis 32(2): 143-149



Brain metastases from non-small cell lung cancer (NSCLC) are associated with a poor prognosis. In selected cases, surgical resection of brain metastases may be indicated, but the identification of patients suitable for surgery remains difficult. We collected data on patient and tumour characteristics known or suspected to be associated with survival by chart review. Data was merged with available data from the local cancer registry. We identified 64 NSCLC patients with resected brain metastases. Median overall survival after resection was 9.1 months with only two patients (3%) surviving more than 71 and 80 months. One and 2-year survival were 42 and 12.5%. Median survival for males and patients with more comorbidities was shorter (8 vs. 10 months [p = 0.11] and 6 vs. 9 months [p = 0.06]). Patients with squamous cell carcinomas (33% of the patients) had a significantly worse survival than patients with other histologies (7 vs. 10 months [p = 0.02]) with no patient living longer than 2 years. Squamous cell histology was associated with worse prognosis after resection of brain metastases in patients with non-small cell lung cancer. Histology, among other parameters, may also be taken into account when choosing the appropriate patients for resection of brain metastases.

(PDF emailed within 0-6 h: $19.90)

Accession: 058637136

Download citation: RISBibTeXText

PMID: 25628027

DOI: 10.1007/s10585-015-9699-0


Related references

Early whole brain concomitant radiotherapy-chemotherapy for non-small cell lung cancer (NSCLC) brain metastases. A phase 2 study. Lung Cancer 29(1): 100-101, 2000

Phase II with Taxol (Paclitaxel) (T), Carboplatin (C) and brain radiotherapy (RT) in patients (PTS) with inoperable brain metastases (BM) of non-small cell lung cancer (NSCLC). Lung Cancer 29(1): 259-260, 2000

The effect of non-small cell lung cancer histology on survival as measured by the graded prognostic assessment in patients with brain metastases treated by hypofractionated stereotactic radiotherapy. Radiation Oncology 11: 92, 2017

Treatment of brain metastases from non-small-cell lung cancer (NSCLC): radiotherapy. Lung Cancer 45 Suppl 2: S247-S252, 2004

Outcome and prognostic factors in patients with brain metastases from small-cell lung cancer treated with whole brain radiotherapy. Journal of Neuro-Oncology 134(1): 205-212, 2017

Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial. Lancet 388(10055): 2004-2014, 2016

Whole brain radiotherapy-based combined modality treatment of brain metastases from non-small cell lung cancer: a retrospective analysis of prognostic factors. Oncology Research and Treatment 38(1-2): 35-40, 2015

Meta-analysis of whole-brain radiotherapy plus temozolomide compared with whole-brain radiotherapy for the treatment of brain metastases from non-small-cell lung cancer. Cancer Medicine 7(4): 981-990, 2018

Prognostic indices in stereotactic radiotherapy of brain metastases of non-small cell lung cancer. Radiation Oncology 10: 244, 2016

Treatment of brain metastases in patients with non-small cell lung cancer (NSCLC) by stereotactic linac-based radiosurgery: prognostic factors. Lung Cancer 37(1): 87-94, 2002

Prolonged survival after resection and radiotherapy for solitary brain metastases from non-small-cell lung cancer. Australasian Radiology 51(2): 186-189, 2007

Stereotactic radiosurgery (SRS) alone versus whole brain radiotherapy plus SRS in patients with 1 to 4 brain metastases from non-small cell lung cancer stratified by the graded prognostic assessment: A meta-analysis (PRISMA) of randomized control trials. Medicine 97(33): E11777, 2018

Generation of a New Disease-specific Prognostic Score for Patients With Brain Metastases From Small-cell Lung Cancer Treated With Whole Brain Radiotherapy (BMS-Score) and Validation of Two Other Indices. Clinical Lung Cancer 19(4): 340-345, 2018

Brain Metastases of Non-Small Cell Lung Cancer: Prognostic Factors in Patients with Surgical Resection. Journal of Neurological Surgery. Part A, Central European Neurosurgery 79(2): 101-107, 2017

Radiolabeled cetuximab plus whole-brain irradiation (WBI) for the treatment of brain metastases from non-small cell lung cancer (NSCLC). Strahlentherapie und Onkologie 186(8): 458-462, 2010